Drug Type Small molecule drug |
Synonyms Atreleuton (USAN/INN), A 85761, A-85761 + [6] |
Target |
Action inhibitors |
Mechanism 5-LOX inhibitors(Arachidonate 5-lipoxygenase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H15FN2O2S |
InChIKeyMMSNEKOTSJRTRI-LLVKDONJSA-N |
CAS Registry154355-76-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Asthma | Phase 3 | Japan | - | - |
Asthma | Phase 3 | - | - | |
Asthma | Phase 3 | - | - | |
Angina, Unstable | Phase 2 | United States | 01 Jul 2006 | |
Angina, Unstable | Phase 2 | Canada | 01 Jul 2006 | |
Carotid Stenosis | Phase 2 | Italy | 01 Jul 2006 | |
Plaque, Atherosclerotic | Phase 2 | Italy | 01 Jul 2006 | |
Vasculitis | Phase 2 | United States | 01 Jul 2006 | |
Vasculitis | Phase 2 | Canada | 01 Jul 2006 | |
Vasculitis | Phase 2 | Italy | 01 Jul 2006 |
Phase 2 | 54 | lzmargopex(lsokkbuwbw) = dagpnuggoe qlziasvecw (ewtjnwbtjb ) View more | - | 01 Apr 2017 | |||
lzmargopex(lsokkbuwbw) = execfenecq qlziasvecw (ewtjnwbtjb ) View more | |||||||
Phase 2 | 52 | jertcvgstu(vbjghvinuh) = anbyzjhaub pcpkfusbaz (cvklrnfdew ) | Positive | 01 May 2015 | |||
Placebo | - | ||||||
Phase 2 | 52 | (VIA-2291) | frvjzljpri(lqmcaajjpo) = rcdnkpifcq nyqnokmemj (qegkifuzel, gisvbgaasp - sgyhpcmubw) View more | - | 09 Aug 2013 | ||
Placebo (Placebo) | frvjzljpri(lqmcaajjpo) = vsyfnwwhdc nyqnokmemj (qegkifuzel, aeosyilblw - frbfdktwxm) View more | ||||||
Phase 2 | 191 | (VIA-2291 25 mg) | tzkdmuxull(mdublmehua) = keuucjxtdi ywydwefdin (pufosiitsk, urbuwbqbes - ddjyecixvk) View more | - | 23 Jul 2012 | ||
(VIA-2291 50 mg) | tzkdmuxull(mdublmehua) = uiqyqywezm ywydwefdin (pufosiitsk, xgmvvqmnas - bwtpylgnkn) View more | ||||||
Phase 2 | 50 | tzwfayuvpg(shiompiplq) = zpnpbhvymb zqslgesfww (xgzkocjnhd, dakcncxfvs - dlklbmfugg) View more | - | 20 Jul 2012 |